轻度认知障碍患者的针:一个随机的,患者评估者盲目的,假控制的试点研究
Yujin Choi1, Pyung-Wha Kim1, In-Chul Jung2
1KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.
BMC complementary medicine and therapies
|July 19, 2025
概括
这项试点研究发现针可用于轻度认知障碍 (MCI),显示出潜在的记忆益处. 需要进行更大规模的试验来确认针.
科学领域:
- 神经学 神经学
- 综合医学是一个整体医学.
- 临床试验 临床试验
背景情况:
- 轻度认知障碍 (MCI) 是正常衰老和痴呆症之间的关键阶段.
- 针是一种潜在的MCI非药物干预,但需要有力的证据.
- 高质量的研究对于验证针在治疗MCI中的有效性至关重要.
研究的目的:
- 评估针治疗轻度认知障碍 (MCI) 的可行性.
- 评估针对MCI患者认知功能的影响.
- 为了确定针在MCI人群中的安全性和耐受性.
主要方法:
- 一个随机的,患者和评估者盲目的,假控制的试验试验.
- 30名患有MCI的参与者被随机分配到针或假针12周 (24次).
- 主要结局:阿尔茨海默病评估尺度-认知子尺度 (ADAS-cog) 的变化;次要结局:首尔神经心理查电池 (SNSB-II),不良事件,令人眼花乱的成功.
主要成果:
- 30名参与者中有28人完成了这项研究,这表明可行性很好.
- 两组都显示ADAS-cog得分有临床意义的下降;两组之间没有显著差异 (P=0.6590).
- SNSB-II记忆域显示了适度的效果大小有利于针 (科恩d=0.57,P=0.1317),没有报告的不良事件.
结论:
- 12周的针治疗对于患有MCI的患者来说是可行的.
- 虽然主要的认知结果在统计学上并不显著,但二次测量表明潜在的记忆改善.
- 需要进行更大规模的证实性试验,以确定针对MCI的最终有效性.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
209
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
209
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262


